NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/Orion Visual Cortical Prosthesis
intracorticalIDEinvestigational

Orion Visual Cortical Prosthesis

Implant Type
intracortical
Electrodes
60
Channels
60
FDA Status
IDE
Clinical Stage
Phase I/II feasibility study (NCT03344848)
Status
investigational
About

The Second Sight Orion is a cortical vision prosthesis that bypasses the eye and optic nerve entirely, stimulating the visual cortex directly to evoke the perception of light flashes (phosphenes) in profoundly blind individuals. A pair of glasses-mounted cameras captures video; a wearable processor converts the image into electrode stimulation patterns transmitted wirelessly to an implanted array on V1 (primary visual cortex). The Orion targets individuals blinded by conditions such as glaucoma, diabetic retinopathy, and optic nerve damage who cannot benefit from retinal prostheses. Second Sight previously marketed the Argus II retinal implant before pivoting to cortical stimulation.

Target Conditions
profound bilateral blindnessglaucomadiabetic retinopathyoptic nerve atrophy
Milestones
2013-02Argus II retinal prosthesis FDA approved (predecessor device)
2018-01Orion cortical prosthesis IDE granted; first human implant
2022-01Second Sight merges with Nano-X; Orion trial continues under new entity
FDA Regulatory Pathway
Investigational Device Exemption (IDE)

An IDE permits a device to be used in a clinical study to collect safety and effectiveness data required for a PMA or 510(k) submission. IDE devices are not approved for commercial sale.

FDA Device Regulatory Guidance ↗
Other intracortical Devices